Bausch & Lomb optimistic on FDA approval for laser
This article was originally published in Clinica
Executive Summary
The share price of eye healthcare company Bausch & Lomb rose by nearly 8% last week on the announcement that the company was "highly confident" that the US FDA would waive a panel review of its pre-market approval application by the ophthalmic devices panel for its laser for LASIK refractive surgery procedures.